Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
Matt Stevenson,1* Rachel Archer,1 Jon Tosh,1 Emma Simpson,1 Emma Everson-Hock,1 John Stevens,1 Monica Hernandez-Alava,1 Suzy Paisley,1 Kath Dickinson,1 David Scott,2 Adam Young3 and Allan Wailoo1
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK 2Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK 3Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
*Corresponding author
Corrigendum issued November 2016 Corrigendum DOI: 10.3310/hta20350-c201611 Original DOI: 10.3310/hta20350 This report should be referenced as follows:
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 2016;20(35). Corrigendum in Health Technol Assess 2016;20(35):611–614.
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine. DOI: 10.3310/hta20350-c201611 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
Corrigendum notice
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young and Allan Wailoo
This paper1 is corrected as follows:
Table 209: Information in this table has been updated.
TABLE 209 Deterministic base-case results using EULAR data directly: ERAS cDMARD HAQ progression and a moderate, MTX-experienced, RA population
First intervention CPQ compared with in the strategy Discounted costs Discounted QALYs MTX strategy (£) Incremental CPQ (£) MTX CiC information has CiC information has –– been removed been removed TCZ + MTX CiC information has CiC information has 51,559 Extendedly dominated been removed been removed ABT i.v. + MTX CiC information has CiC information has 47,533 47,533 been removed been removed IFX + MTX CiC information has CiC information has 48,424 Dominated been removed been removed ADA + MTX CiC information has CiC information has 51,472 Dominated been removed been removed CTZ + MTX CiC information has CiC information has 50,467 Extendedly dominated been removed been removed GOL + MTX CiC information has CiC information has 51,111 Extendedly dominated been removed been removed ETN + MTX CiC information has CiC information has 51,436 95,714 been removed been removed CPQ, cost per QALY gained.
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 613 provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. DOI: 10.3310/hta20350-c201611 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 35
Reference
1. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 2016;20(35).
614
NIHR Journals Library www.journalslibrary.nihr.ac.uk